EDN1 and essential hypertension: ET-1 blocking with bosentan led to a decrease in BP in hypertensive patients [323]; nevertheless, it also diminished BP in essential hypertension subjects with normal ET-1 levels [324], potentially indicating that plasma ET-1 levels do not show the real state of endothelin action.